{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:29:56Z","timestamp":1786480196787,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"DOI":"10.13039\/100000062","name":"HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["1R01DK112984"],"award-info":[{"award-number":["1R01DK112984"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["1I01BX003698"],"award-info":[{"award-number":["1I01BX003698"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data regarding the benefits or harm associated with the continuation of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), especially the effect on inflammation, in patients who are hypertensive and hospitalized with coronavirus disease 2019 (COVID-19) in the United States are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-center cohort study of patients sequentially hospitalized with COVID-19 at Stony Brook University Medical Center from March 7, 2020 to April 1, 2020, inclusive of these dates. Data collection included history of known comorbidities, medications, vital signs, and laboratory values (at admission and during the hospitalization). Outcomes include inflammatory burden (composite scores for multiple markers of inflammation), AKI, admission to the intensive care unit (ICU), need for invasive mechanical ventilation, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 300 patients in the study cohort, 80 patients (27%) had history of ACEI or ARB use before admission, with 61% (49\/80) of these patients continuing the medications during hospitalization. Multivariable analysis revealed that the history of ACEI or ARB use before hospitalization was not associated with worse outcomes. In addition, the continuation of these agents during hospitalization was not associated with an increase in adverse outcomes and predicted fewer ICU admissions (odds ratio, 0.25; 95% CI, 0.08 to 0.81) with a decrease in the severity of inflammatory burden (peak C-reactive protein, 6.9\u00b13.1 mg\/dl,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.03; peak inflammation score, 2.3\u00b11.1 unit reduction,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Use of ACEI or ARBs before hospitalization was not associated with adverse outcomes in COVID-19, and the therapeutic benefits of continuing ACEI or ARB in patients hospitalized with COVID-19 was not offset by adverse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0003792020","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T21:52:17Z","timestamp":1592862737000},"page":"801-809","source":"Crossref","is-referenced-by-count":26,"title":["Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection"],"prefix":"10.34067","volume":"1","clinical-trial-number":[{"clinical-trial-number":"nct04312009","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04366050","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Imran","family":"Chaudhri","sequence":"first","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh M.","family":"Koraishy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Bolotova","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanwoo","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Marcos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Taub","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haseena","family":"Sahib","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Bloom","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Skopicki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Mallipattu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"},{"name":"Renal Section, Northport Veterans Affairs Medical Center, Northport, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"m606","DOI":"10.1136\/bmj.m606","article-title":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series","volume":"368","author":"Xu","year":"2020","journal-title":"BMJ"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers","volume":"75","author":"Danser","year":"2020","journal-title":"Hypertension"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2215\/CJN.03530320","article-title":"Sound science before quick judgement regarding RAS blockade in COVID-19","volume":"15","author":"Sparks","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response","volume":"14","author":"Astuti","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic","volume":"16","author":"South","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1042\/CS20130436","article-title":"Angiotensin-(1-7) and angiotensin-(1-9): Function in cardiac and vascular remodelling","volume":"126","author":"McKinney","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B11-20230821","article-title":"A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1\/ACE2 imbalance [published online ahead of print Apr 24, 2020]","author":"Sriram","journal-title":"Br J Pharmacol"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"m1966","DOI":"10.1136\/bmj.m1966","article-title":"Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York city: prospective cohort study","volume":"369","author":"Petrilli","year":"2020","journal-title":"BMJ"},{"key":"B14-20230821","article-title":"Potential effects of coronaviruses on the cardiovascular system: A review [published online ahead of print March 27, 2020]","author":"Madjid","journal-title":"JAMA Cardiol"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"B21-20230821","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1177\/2047487317728766","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis","volume":"24","author":"Salvador","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4266\/kjccm.2016.00976","article-title":"Effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J Crit Care Med"},{"key":"B24-20230821","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/SHK.0b013e318189017a","article-title":"Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases","volume":"31","author":"Shen","year":"2009","journal-title":"Shock"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2009.08.037","article-title":"Associations of inflammatory markers with coronary artery calcification: Results from the Multi-Ethnic Study of Atherosclerosis","volume":"209","author":"Jenny","year":"2010","journal-title":"Atherosclerosis"},{"key":"B28-20230821","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"e000406","DOI":"10.1136\/fmch-2020-000406","article-title":"Clinicopathological characteristics of 8697 patients with COVID-19 in China: A meta-analysis","volume":"8","author":"Zhu","year":"2020","journal-title":"Fam Med Community Health"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"B33-20230821","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.autrev.2020.102569","article-title":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review","volume":"19","author":"Alijotas-Reig","year":"2020","journal-title":"Autoimmun Rev"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0003792020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:57:01Z","timestamp":1786478221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0003792020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0003792020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}